Disruptive precision medicine technology conquering inflammation and diabetes
Josep Bassaganya- Riera
President and CEO
- 17 years of business development and fundraising experience in leading biotech companies.
- Developed innovative large-scale translational programs with focus on immune modulators, anti-inflammatories and anti-diabetic therapeutics.
- Identified and validated the role of novel therapeutic targets in diabetes and inflammatory bowel disease yielding over 15 patents.
- Experience in bioinformatics, computational modeling, pre-clinical efficacy and safety studies (rats mouse and pig models) as well as human clinical trials.
- Please email me at email@example.com
Back to top